Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Shein Shares Slide 9% in Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Amazon Secures 200 MW Wind Power Deals in Sweden 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
LAWRENCEVILLE, N.J., March 20, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Tuesday, March 27, 2018. To participate in the call, interested parties may dial 1-888-737-3628 (Toll-Free/North America) or 1-719-325-4879 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2017 Earnings Call (Conference Code: 1256084) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Tuesday, March 27, 2018 and will remain available until Tuesday, April 10, 2018. The replay can be accessed at 1-719-457-0820 or 1-719-785-5608 using Conference ID: 1256084. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Tuesday, March 27, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
